Glenn Buterbaugh, MD
Hand Surgery · Wexford, PANPI 1528020187
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,000 of the $10,263 with a category attached, or 77.9%. Arthrex accounts for 88.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $8,506 and has fallen 96.8% since, to $271 in 2025.
Across 101 payments — averaging $101.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$9K
- Stryker$262
- US Implant Solutions, LLC$232
- Endo Pharmaceuticals Inc.$218
- Medartis Inc.$125
- Endo USA, Inc.$89
- plus $272 from 10 others
What the payments were for
- Speaking & faculty fees$8,00078%
- Travel & lodging$551%
- Food & beverage$2,20822%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 57 | $9,065 |
| Stryker | 7 | $262 |
| US Implant Solutions, LLC | 1 | $232 |
| Endo Pharmaceuticals Inc. | 15 | $218 |
| Medartis Inc. | 1 | $125 |
| Endo USA, Inc. | 5 | $89 |
| Electronic Waveform Lab, Inc. | 3 | $50 |
| Axogen | 3 | $47 |
| Sonex Health, Inc. | 1 | $34 |
| Zimmer Biomet | 1 | $34 |
| Medline Industries LP | 1 | $24 |
| Anika Therapeutics, Inc. | 1 | $22 |
| Smith+Nephew | 1 | $19 |
| AbbVie | 1 | $15 |
| Nalu Medical, Inc. | 2 | $15 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,263 in reported general payments places this provider in the 65th percentile of 110 hand surgery providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylprednisolone | 73 | $420 |
| Ibuprofen | 11 | $137 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $42 |
| Diazepam | 13 | $6 |
Paid to pharmacies, not to this prescriber.
Other hand surgery in Wexford
- James MullenWexford$43K
- Thomas GrahamAllentown$1.4M
- Randall CulpPlains$358K
- Asif IlyasBryn Mawr$295K
- Arthur OstermanKing Of Prussia$198K
- Meredith OstermanKing Of Prussia$196K
- Adam StrohlPhiladelphia$175K
- Mark BaratzPittsburgh$112K
- Richard TostiBryn Mawr$109K
- Sidney JacobyKing Of Prussia$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.